Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MediWound Ltd. (MDWD) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. MediWound files reports on Form 6-K to furnish press releases, financial statements, and transaction details, and uses shelf registration statements on Form F-3 and employee share plans on Form S-8 for capital markets activities. These documents provide structured insight into the company’s biotechnology business focused on enzymatic, non-surgical therapies for tissue repair.
In its Form 6-K filings, MediWound furnishes quarterly and interim financial results, including condensed consolidated statements of financial position and profit or loss, along with management press releases discussing revenue, operating loss, cash balances, and non-IFRS measures such as Adjusted EBITDA. Other 6-Ks describe registered direct offerings of ordinary shares under an effective Form F-3 shelf registration statement, including purchase agreements, use of proceeds for EscharEx® pre-commercial activities and manufacturing expansion, and related legal opinions.
Filings also reference government-supported programs and contracts that are important to MediWound’s burn and chronic wound portfolio. BARDA- and U.S. Department of Defense-funded projects for NexoBrid®, including clinical development, regulatory submissions, emergency procurement, and formulation work, are discussed in the company’s press releases that are incorporated by reference into SEC reports. Insider share purchases by senior leadership are reported on Form 6-K, providing transparency into management’s trading activity.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain key points from lengthy filings, highlight changes in financial condition, and surface important details about offerings, grants, and clinical or manufacturing milestones. Users can quickly locate quarterly updates, registration statements, and reports that reference NexoBrid and EscharEx, and review how MediWound describes its risks, funding, and strategic priorities over time.
MediWound Ltd. reports that its North America distributor Vericel has been awarded a ten-year BARDA contract valued at up to $197 million related to burn treatment product NexoBrid.
According to Vericel, the contract covers NexoBrid procurement for the U.S. Strategic National Stockpile, a Vendor Managed Inventory system, development of a next generation formulation, an additional indication such as blast trauma injuries, and design and validation of a potential U.S.-based manufacturing facility.
Vericel reported that the base period totals $35 million, including about $10 million over the next 12 months for initial NexoBrid procurement and VMI establishment. MediWound notes these statements are based on Vericel’s reports and highlights typical clinical, regulatory, commercial and BARDA-related uncertainties.
MediWound Ltd. has called its 2026 annual general meeting of shareholders for May 6, 2026 in New York. Investors will vote on re-electing five directors, reappointing Somekh Chaikin (KPMG member firm) as independent auditor for 2026, and approving an annual cash bonus of approximately $206,000 for CEO Ofer Gonen based on 2025 performance.
The company will also present its audited consolidated financial statements for the year ended December 31, 2025, as previously filed in its Form 20-F. Shareholders of record at the close of business on March 31, 2026 are entitled to vote, with one vote per ordinary share.
MediWound Ltd. director Vickie Rae Driver filed an initial ownership report detailing her equity interests in the company. She directly holds ordinary shares, including shares underlying restricted stock units granted on March 4, 2026 that vest in full one year after the grant date.
She also holds several stock option awards to buy ordinary shares at exercise prices ranging from 11.8850 to 37.5200 per share, with expiration dates between 2030 and 2036. This filing records existing holdings and does not show any new purchases or sales.
MediWound Ltd. Chief Financial Officer Hana Luxenburg Kalfon filed an initial Form 3 reporting her equity holdings in the company. She directly holds stock options over 39,000, 32,681, 24,000 and 26,000 ordinary shares at exercise prices of $11.9000, $12.7290, $18.5400 and $17.6000, expiring between May 2033 and March 2036. She also holds 4,085, 3,000 and 3,200 ordinary shares underlying restricted share units granted in 2024, 2025 and 2026, which vest 25% after one year and then 6.25% quarterly over four years.
MediWound Ltd.’s Chief Medical Officer, Ety Klinger, filed an initial Form 3 showing equity holdings in ordinary shares, stock options, and restricted share units. The filing lists multiple option grants to buy ordinary shares, including 3,571 underlying shares at an exercise price of 36.0500 that expire on December 31, 2028, and 5,491 underlying shares at 12.2500 that expire on April 23, 2030, along with several later-dated grants through March 4, 2036.
Footnotes describe RSU awards granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the first anniversary of grant and 6.25% quarterly over the following three years. The filing also records direct holdings of ordinary shares in several line items.
MediWound Ltd. director David Morton Fox filed an initial statement of beneficial ownership, outlining his equity stake in the company. He directly holds ordinary shares and additional ordinary shares underlying restricted stock units that were granted on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Fox also reports a series of equity incentives. These include Series A warrants$13.4750 per share, expiring on November 28, 2026. He holds multiple stock option grants, such as options over 14,285 ordinary shares at $12.2500 per share expiring on June 29, 2030, and other tranches with exercise prices between $11.8850 and $37.5200 expiring from 2031 through 2036. This filing records existing holdings and does not show new market transactions.
MediWound Ltd. VP Clinical & Reg. Affairs Aya Ben Yaakov filed an initial Form 3 reporting existing equity holdings in the company. The filing lists several stock options to buy ordinary shares at exercise prices between 12.25 and 37.52 with expirations from 2028 to 2036, plus ordinary shares, including amounts underlying RSUs. Footnotes explain that these RSUs and options vest over four years, with 25% vesting after one year and 6.25% vesting quarterly thereafter. The filing shows holdings only, without any reported purchases or sales.
MediWound Ltd. executive Meyer Yaron, EVP, General Counsel and Corporate Secretary, filed an initial Form 3 reporting his beneficial ownership in ordinary shares and stock options of MDWD.
The filing lists several stock option grants to buy ordinary shares, including options over 2,857 underlying shares at an exercise price of 36.0500 expiring on December 31, 2028, and 4,919 underlying shares at 12.2500 expiring on April 23, 2030. Additional grants cover 2,769 underlying shares at 37.5200 expiring on March 4, 2031, 9,230 underlying shares at 14.4200 expiring on May 16, 2032, and further awards expiring through 2036.
Yaron also reports direct holdings of ordinary shares tied to restricted stock units (RSUs). Footnotes explain RSU and option grants made on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the one-year anniversary of grant and 6.25% quarterly thereafter until fully vested after four years.
MediWound Ltd. filed an initial ownership report for director Stephen T. Wills, detailing his existing holdings in ordinary shares and stock options. The filing lists multiple stock option awards on ordinary shares with exercise prices ranging from 11.8850 to 37.5200 and expiration dates between 2029 and 2036. It also notes ordinary shares underlying RSUs and an option grant made on March 4, 2026 that vest 100% on the one-year anniversary of the grant date, showing his current equity-based alignment with the company.
MediWound Ltd. director Samuel Rubinstein filed an initial Form 3 reporting his equity holdings in the company. He holds stock options over 7,200, 7,542, 5,600 and 6,250 ordinary shares at exercise prices of $9.6400, $12.7290, $18.5400 and $17.6000, expiring between 2033 and 2036. He also holds 2,843 and 750 ordinary shares directly, plus 525 ordinary shares held indirectly by his spouse. Footnotes state that certain ordinary shares are underlying RSUs granted on March 4, 2026, and certain options were also granted on that date, with each grant vesting 100% on the one-year anniversary of the grant date.